| Patient ID | Drug resistance profile | Anti-TB regimen | Sputum smear conversion days | Sputum culture conversion days | Linezolid exposure days | Adverse events |
| 1 | H, R, EMB, ETH | AMK, LZD, MFX, PZA, TER | 25 | 47 | 44 | |
| 2 | H, R, S, EMB, PZA, FQ, ETH, AMK, KM | AM, CLOF, LEVO, LZD, MRP, TER | 54 | 120 | 77 | Anaemia, leukopenia |
| 3 | H, R, S, EMB, PZA, CS | AMK, ETH, LZD, MFX, MRP, PAS | 5 | No conversion | 50 | |
| 4 | H, R, S, EMB, FQ, ETH, AMK, CM, KM | AM, CLOF, CS, LZD, MFX, MRP, PZA | 23 | 38 | 110 | |
| 5 | H, R, PZA, FQ, ETH, PAS, CM | AM/Cl, AMK, CS, ETH, LZD, MFX, MRP | 35 | No conversion | 50 | |
| 6 | H, R, S, EMB, FQ, ETH, AMK, PAS, CM, KM | AM, CLOF, LZD, MFX, MRP, PZA | 74 | 95 | 174 | |
| 7 | H, R, S, EMB, PZA, ETH, PAS, KM | AM, AMK, CLOF, CS, LZD, MFX, MRP | 46 | 70 | 83 | |
| 8 | H, R, S, PZA, FQ, ETH, PAS, KM | AM, AMK, CLOF, CS, EMB, LZD, MRP | 34 | 44 | 90 | |
| 9 | H, R, S, EMB, PZA, CS, PAS, KM | AM, AMK, ETH, LZD, MRP, TER | 22 | 37 | 20 | Low platelets (LZD temporary interruption) |
| 10 | H, R, S, PZA, FQ, PAS | AMK, EMB, ETH, LZD, MFX, TER | 52 | 84 | 20 | Neuropathy (LZD temporary interruption) |
| 11 | H, R, S, EMB, PZA, PAS | AM, AMK, ETH, LZD, MFX, MRP | 147 | No conversion | 30 | |
| 12 | H, R, S, EMB, PZA, FQ, ETH, CS, PAS | AM, AMK, CLOF, ETH, LZD, MFX, MRP, PZA | 139 | 150 | 120 | Neuropathy |
AM: amoxicillin; AM/Cl: amoxicillin/clavulanate acid; AMK: amikacin; CLOF: clofazimine; CM: capreomycin; CS: cycloserine; EMB: ethambutol; ETH: ethionamide; FQ: any fluoroquinolone; H: isoniazid; KM: kanamycin; LEVO: levofloxacin; LZD: linezolid; MFX: moxifloxacin; MRP: meropenem; PAS: p-aminosalicylic acid; PZA: pyrazinamide; R: rifampicin; S; streptomycin; TER: terizidone.